<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Genomics</journal-id><journal-title-group><journal-title>BMC Genomics</journal-title></journal-title-group><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4559210</article-id><article-id pub-id-type="publisher-id">1881</article-id><article-id pub-id-type="doi">10.1186/s12864-015-1881-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ma</surname><given-names>Xian-Yong</given-names></name><address><email>xian-yong.ma@yale.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jian-Hui</given-names></name><address><email>jianhui.wang@yale.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jing-Lan</given-names></name><address><email>jinglan.wang@yale.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Charles X</given-names></name><address><email>xiaodong88ma@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiao-Chun</given-names></name><address><email>xiaochun.wang@yale.edu</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Feng-Song</given-names></name><address><email>liufengsong@hbu.edu.cn</email></address><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Pathology, Yale University School of Medicine, New Haven, USA </aff><aff id="Aff2"><label/>University of Connecticut School of Medicine, Farmington, USA </aff><aff id="Aff3"><label/>Department of Surgical Oncology, Affiliated Hospital of Hebei University, Baoding, China </aff><aff id="Aff4"><label/>College of Life Sciences, Hebei University, Baoding, China </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><issue>1</issue><elocation-id>676</elocation-id><history><date date-type="received"><day>13</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Ma et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The metastasis-associated lung adenocarcinoma transcription 1 (Malat1) is a highly conserved long non-coding RNA (lncRNA) gene. Previous studies showed that Malat1 is abundantly expressed in many tissues and involves in promoting tumor growth and metastasis by modulating gene expression and target protein activities. However, little is known about the biological function and regulation mechanism of Malat1 in normal cell proliferation.</p></sec><sec><title>Results</title><p>In this study we conformed that Malat1 is highly conserved across vast evolutionary distances amongst 20 species of mammals in terms of sequence, and found that mouse Malat1 expresses in tissues of liver, kidney, lung, heart, testis, spleen and brain, but not in skeletal muscle. After treating erythroid myeloid lymphoid (EML) cells with All-trans Retinoic Acid (ATRA), we investigated the expression and regulation of Malat1 during hematopoietic differentiation, the results showed that ATRA significantly down regulates Malat1 expression during the differentiation of EML cells. Mouse LRH (Lin-Rhodamine<sup>low</sup> Hoechst<sup>low</sup>) cells that represent the early-stage progenitor cells show a high level of Malat1 expression, while LRB (Lin&#x02009;<bold>&#x02212;</bold>&#x02009;Hoechst<sup>Low</sup> Rhodamine<sup>Bright</sup>) cells that represent the late-stage progenitor cells had no detectable expression of Malat1.</p><p>Knockdown experiment showed that depletion of Malat1 inhibits the EML cell proliferation. Along with the down regulation of Malat1, the tumor suppressor gene p53 was up regulated during the differentiation. Interestingly, we found two p53 binding motifs with help of bioinformatic tools, and the following chromatin immunoprecipitation (ChIP) test conformed that p53 acts as a transcription repressor that binds to Malat1&#x02019;s promoter. Furthermore, we testified that p53 over expression in EML cells causes down regulation of Malat1.</p></sec><sec><title>Conclusions</title><p>In summary, this study indicates Malat1 plays a critical role in maintaining the proliferation potential of early-stage hematopoietic cells. In addition to its biological function, the study also uncovers the regulation pattern of Malat1 expression mediated by p53 in hematopoietic differentiation. Our research shed a light on exploring the Malat1 biological role including therapeutic significance to inhibit the proliferation potential of malignant cells.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Malat1</kwd><kwd>lncRNA</kwd><kwd>ATRA</kwd><kwd>Hematopoiesis</kwd><kwd>EML</kwd><kwd>p53</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>The long noncoding RNA Malat1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1), also known as NEAT2 (Nuclear-Enriched Abundant Transcript 2) or alpha, is a highly conserved and large-size nuclear noncoding RNA (lncRNA) molecule. This gene was firstly identified in 2003 from early-stage non-small cell lung cancer (NSCLC) cells with highly expression level [<xref ref-type="bibr" rid="CR1">1</xref>], subsequently a number of publications reported that Malat1 is also as one of the major genes that highly up regulates in different cancers including endometrial cancer [<xref ref-type="bibr" rid="CR2">2</xref>], breast cancer [<xref ref-type="bibr" rid="CR3">3</xref>]; cervical cancer [<xref ref-type="bibr" rid="CR4">4</xref>]; colorectal cancer [<xref ref-type="bibr" rid="CR5">5</xref>]; hepatocellular carcinoma [<xref ref-type="bibr" rid="CR6">6</xref>]; liver cancer [<xref ref-type="bibr" rid="CR7">7</xref>]; neuroblastoma [<xref ref-type="bibr" rid="CR8">8</xref>]; osteosarcoma [<xref ref-type="bibr" rid="CR9">9</xref>], pancreatic cancer [<xref ref-type="bibr" rid="CR10">10</xref>], prostate cancer [<xref ref-type="bibr" rid="CR11">11</xref>], bladder cancer [<xref ref-type="bibr" rid="CR12">12</xref>], and gastric cancer [<xref ref-type="bibr" rid="CR13">13</xref>]. Targeted deletion of Malat1 in human lung tumor cells impairs tumor metastasis in a mouse xenograft model [<xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, expression of Malat1 correlates with tumor development, progression, metastasis and survival in different cancer types. In addition to the important role in proliferation and metastases of cancers, Malat1 also involves in other diseases and even in normal physiological processes of cells, for example: It has been reported that knockdown of Malat1 using siRNA suppresses myoblast proliferation by arresting cell growth in the G(0)/G(1) phase [<xref ref-type="bibr" rid="CR15">15</xref>], thus target therapy of this gene shows a potential value for recovery of muscle atrophy or muscle wasting diseases. In addition, Lin M.Y., et al. [<xref ref-type="bibr" rid="CR16">16</xref>] reported that Malat1 is highly expressed in iPS (induced pluripotent stem cells). In normal tissues, MALAT1 expresses in a tissue specific patterns, for example, Malat1 is the most abundantly expressed lincRNA in differentiating neurons, and is up regulated in cerebellum, hippocampus and brain stem of human alcoholics [<xref ref-type="bibr" rid="CR17">17</xref>]. When treated the mouse brain cells with PCP (psychotomimetic agent phencyclidine, which generally induces the perinatal apoptosis and behavioral deficits), Malat1 is highly up regulated [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Full length Malat1 localizes in nuclear speckles, which is a dynamic structure that is essential for gathering and recruiting splicing factors [<xref ref-type="bibr" rid="CR19">19</xref>], thus, Malat1 RNA was considered to be as an important regulatory molecule for trans splicing of RNA [<xref ref-type="bibr" rid="CR20">20</xref>], Lin M.Y., et al. [<xref ref-type="bibr" rid="CR16">16</xref>] has found that there is a substantial difference in splices isoforms of lncRNA including Malat1 generated in induced pluripotent stem cells (iPSCs) and neurons, these isoforms are specific to different growth status, the physiological function is unknown. As a major lncRNA, Malat1 also joins regulation process of transcription splicing. Malat1 interacts with serine/arginine splicing factors (SF), results in modulating the distribution of splicing factors in nuclear speckle, and changing cellular levels of phosphorylated forms of SR proteins. Researchers have already identified that Malat1 RNA has multiple physiological functions in normal cells, such as regulating cell cycle [<xref ref-type="bibr" rid="CR21">21</xref>], Malat1 modulates the expressions of cell cycle genes, which are required for G1/S regulation and mitotic progression with tissue-specific and developmental stage-specific patterns.</p><p>In addition to associate with malignant phenotype for high expression of wild type of Malat1 RNA, the mutated forms of Malat1 are also involved in malignant phenotype; for example, t (11; 19) (q13.1; q13.42) was been found in mesenchymal hamartoma of liver [<xref ref-type="bibr" rid="CR22">22</xref>], this translocation causes breakpoint in Malat1 gene on chromosome 11, thereafter produces mutated forms of Malat1RNA by fusing Malat1 with MHLB1 gene of chromosome 19. t (6;11) (p21;q12) was reported in renal cell carcinoma [<xref ref-type="bibr" rid="CR23">23</xref>], this translocation causes Malat1 (Alpha)-TFEB gene fusion, results in over expression of native TFEB protein (determined by immuno-histochemistry), while native TFEB in cells without this translocation is not detectable by this assay.</p><p>It has been reported that lncRNAs play critical role in normal differentiation/cell fate decision during hematopoiesis. The first lncRNA with key role in hematopoiesis to be described was EGO [<xref ref-type="bibr" rid="CR24">24</xref>], an evolutionary conserved gene, which transcribes an antisense RNA of ITPR1 gene that modulates the development of eosinophils, EGO is normally expressed in human CD34<sup>+</sup> hESCs and becomes up regulated during their differentiation into eosinophil. Knockdown of EGO by siRNAs in cultured CD34<sup>+</sup> progenitors impairs the expression of those genes including major basic protein and eosinophil-derived neurotoxin, which are critical for eosinophil development. Thus, EGO can contribute to eosinophilopoiesis by enhancing the expression of genes needed for this process. lncRNAs are also implicated in the regulation of myelopoiesis, granulocytosis and monocytosis, Zhang et al. [<xref ref-type="bibr" rid="CR25">25</xref>] identified HOTAIRM1, a gene transcribes an antisense sequence of HOXA1/2 intergenic region, is highly up regulated during retinoic acid-induced granulocytic differentiation of myeloid progenitors. HOTAIRM1 transcript is a ~500&#x000a0;bp RNA fragment, which coordinates along with the activation of HoxA1 and HoxA4 expression during granulocytic differentiation in NB4 cells (acute promyelocytic leukemia cell line) [<xref ref-type="bibr" rid="CR26">26</xref>]. The understanding regarding involvement of Malat1 in hematopoiesis still remains poor. In this study we are addressed to explore Malat1 expression regulation patterns and possible physiological functions in hematopoietic differentiation.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Malat1 is an evolutionary conserved lncRNA and expressed in a wide range of species and tissues of primates</title><p>On mouse chromosome 19, Malat1 gene is located at 40&#x000a0;kb down stream of Neat1 gene (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). Sequence analysis for mouse Malat1 gene shows Malat1 is 6.98&#x000a0;kb transcript, which has been identified both by Northern blot and sequence analysis of transcription. Alignment analysis of multiple genomic sequences shows Malat1 is the most evolutionary conserved sequence in ~120&#x000a0;kb chromosome region (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). The comparison of wide range of species (20 species of mammals) by phylogenetic analysis shows these Malat1 molecules of different resources organisms are from a common ancestor (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Mouse Malat1 has smallest sequence diversity with rat MALAT1, and human Malat1 is very closed to bonobo and chimpanzee Malat1. Highly conserved coding DNA sequence is common known with important physiological functions, but the role for many of these highly conserved long non-coding DNA sequences remains unclear. The conservative of Malat1 sequence indicates it is a house keeping like gene, more and more evidence shows it up regulates in many cancers, and this research also shows Malat1 is highly expression in undifferentiated hematopoietic stem cells. In addition, several publications have described Malat1 regulates the target gene expression via multiple layer and flexible manners [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, we predict that Malat1 plays a critical regulation role on maintenance of proliferation and malignant cell metastasis ability, more experiments need to be carried out to clarify these functions of Malat1 molecule. Through extensive analysis of publicly accessible panoramic expression databases including GEO (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gds">http://www.ncbi.nlm.nih.gov/gds</ext-link>), GeneAtlas (<ext-link ext-link-type="uri" xlink:href="http://biogps.org/dataset">http://biogps.org/dataset</ext-link>), SAGE Genie (<ext-link ext-link-type="uri" xlink:href="http://cgap.nci.nih.gov/SAGE">http://cgap.nci.nih.gov/SAGE</ext-link>), and NHPRTR (Nonhuman Primate Reference Transcriptome Resource, <ext-link ext-link-type="uri" xlink:href="http://www.nhprtr.org/data/2014_NHP_tissuespecific">http://www.nhprtr.org/data/2014_NHP_tissuespecific</ext-link>). We found Malat1 RNA is extensively expressed in different species and tissues of primates including human being. In order to compare the Malat1 expression status in target tissues that we were worked on, we showed the expression abundances of Malat1 RNA in 7 target tissues from 12 primate species based on the datasets of Illumina BodyMap 2 for expression analysis of human Malat1 and NHPRTR for expression analysis of other primates Malat1 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The Malat1 expresses with high level in other vertebrates such as Zebra fish has been reported recently [<xref ref-type="bibr" rid="CR28">28</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Malat1 gene localization, sequence conservation cross vertebrates and evolutionary Pattern. <bold>a</bold> Mouse Malat1 locus is on chromosome 19 (19A), and is localized on 40&#x000a0;kb down stream of Neat1 gene, yields a 6.983&#x000a0;kb of transcript. <bold>b</bold> Sequence comparison indicates Malat1 gene is the most conserved sequence in around 120&#x000a0;kb region of chromosome 19. <bold>c</bold> Phylogenetic analysis of evolution relationship of Malat1 gene among 20 species of mammals, mouse Malat1 has smallest genetic distance with rat Malat1 and closes to human MALAT1 gene</p></caption><graphic xlink:href="12864_2015_1881_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Malat1 expresses in a wide range of species and tissues of primates including human tissue samples. The expression datasets based on RNAseq were used to show the RNA level of Malat1 in different tissues of primates. 7 target tissues were selected as showed in the figure come from 12 different primate species. The Malat1 expression dataset of human tissues are available in NCBI <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/ieb/research/acembly/av.cgi?db=human">http://www.ncbi.nlm.nih.gov/ieb/research/acembly/av.cgi?db=human</ext-link>, and the expression datasets of other primates are available in the transcriptome database of NHPRTR <ext-link ext-link-type="uri" xlink:href="http://www.nhprtr.org/data/2014_NHP_tissuespecific">http://www.nhprtr.org/data/2014_NHP_tissuespecific</ext-link>. The relative expression level of Malat1 RNA was labeled as FPKM (transcript abundances in fragments per kilobase of exon per million fragments mapped)</p></caption><graphic xlink:href="12864_2015_1881_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec4"><title>ATRA induces Malat1 up regulation in EML cells</title><p>In order to induce EML cell differentiation, we treated the cells with 10&#x000a0;mM of ATRA for 0, 6, 12 and 24&#x000a0;h respectively, total RNAs were detected by Northern blot together with RNA from Epro cells. These RNAs represent the different stages of hematopoietic differentiation, as showed in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref> (upper panel), a RNA fragment with the size of ~7&#x000a0;kb was highly expressed in EML (0&#x000a0;h) and EML (6&#x000a0;h) and dramatically decreases in EML (12&#x000a0;h) and EML (24&#x000a0;h), tiny expression of this RNA was detected in Epro cells. The quantitative differences of Malat1 expression level among these induction stages were determined by comparison of signal intensity after normalizing to &#x003b2;-actin control. From these comparisons, we conclude Malat1 expression level in EML cells (0&#x000a0;h) is 21.25 times higher than that in Epro; and 8.5, 4 and 2 times higher than that in EML cells exposed to ATRA for 24, 12 and 6&#x000a0;h respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref> upper and bottom panel).<fig id="Fig3"><label>Fig. 3</label><caption><p>Expression analysis of Malat1 gene in hematopoietic cells. <bold>a</bold> Northern blot showed the expression level of full length Malat1 in ATRA induced EML cells and Epro cells, upper panel: total RNAs from different induction stages of EML cells as designated in the figure. Lower panel: Semi-quantitative analysis of relative expression level for Malat1 gene in indicated EML and Epro cells; <bold>b</bold> Northern blot showed the expression level of full length Malat1 in different populations of mouse bone marrow as indicated in the figure. Upper panel: total RNA from LRH+, LRH-/(LRH) and LRH-/(LRB) were detected with Malat1probe. Lower panel: semi-quantitative analysis of relative expression level for Malat1 gene in these populations. <bold>c</bold> Northern blot showed the expression level for Malat1 gene in multiple tissues of mouse. Upper panel: total RNA from mouse tissues as showed in the figure was detected. Lower panel: semi-quantitative analysis of relative expression level for Malat1 gene in mouse tissues. 225&#x000a0;bp 5&#x02019; Malat1 DNA was used as the probe to detect the Malat1 expression, a ~6.9&#x000a0;kb Malat1 RNA was labeled in the figures, the data was been normalized using &#x003b2;-actin, for further details see material and methods</p></caption><graphic xlink:href="12864_2015_1881_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec5"><title>Malat1 expresses at high level in early stage of primitive progenitor cells in bone marrow and higher level in liver than in most of other tissues</title><p>Malat1 down regulates during hematopoietic differentiation induced by ATRA, if this expression behavior also existed in normal hematopoietic differentiation? We isolated linage negative populations (Lin-) of mouse bone marrow by using the Lin&#x02009;+&#x02009;antibodies cocktails, the Lin-populations was further isolated by using fluorescence dye Rhodamine-123 and Hoechst-33342 as described in material and methods. Our northern analysis shows Malat1 expresses with much higher level in more primitive progenitor cells (LRH), the expression level in LRH population is 40 fold higher than in LRB and 5 fold higher than in Lin&#x02009;+&#x02009;population (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref> upper and bottom panel). Analysis of multiple tissues shows Malat1 expresses with the highest level in liver, and no detectable expression in skeletal muscle, among tissues assayed in this experiment, the expression level of Malat1 from high to low lists as following: liver&#x02009;&#x0003e;&#x02009;Kidney&#x02009;&#x0003e;&#x02009;lung&#x02009;&#x0003e;&#x02009;heart&#x02009;&#x0003e;&#x02009;testis&#x02009;&#x0003e;&#x02009;spleen&#x02009;&#x0003e;&#x02009;brain&#x02009;&#x0003e;&#x02009;skeletal muscle (See Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref> upper and bottom panel).</p></sec><sec id="Sec6"><title>Hematopoietic differentiation induced by ATRA causes up regulation of p53 and inhibition of EML cell growth</title><p>ATRA treated EML cells induces hematopoietic differentiation [<xref ref-type="bibr" rid="CR29">29</xref>]. We tested the hematopoietic factor GATA2, which is a critical transcription factor for primitive hematopoiesis procedure [<xref ref-type="bibr" rid="CR30">30</xref>]. Our data shows that ATRA exposed significantly up regulates GATA2 expression in EML cells (after 48&#x000a0;h exposed, the expression level of GATA2 is up regulated to around 5 times of uninduced EML cells) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Since it has been identified that GATA2 is one of the indicator of hematopoiesis of yolk sac stem cells and hematopoietic progenitor cells, therefore ATRA exposed initiates hematopoiesis of EML cells. We were also further tested the expression behavior of EKLF1 (erythroid kruppel like factor), which drives red blood cell differentiation and represses megakaryocyte formation [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The results show EKLF1 is up regulated to around 4.5 times of uninduced EML cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>), that implicates the direction of differentiation is more towards blood cells than megakaryocytes. Analysis for growth rate of ATRA-induced EML cells shows an inhibition effect as showed in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>, the proliferation rate of EML cells is decreased around 50&#x000a0;% after 48-h treatment with ATRA (<italic>P</italic>&#x02009;=&#x02009;0.0086&#x02009;&#x0003c;&#x02009;0.05).<fig id="Fig4"><label>Fig. 4</label><caption><p>The analysis of gene expression and cell proliferation. <bold>a</bold> EML cell&#x000a0;were induced with ATRA for indicated time points. The expression of p53, Malat1, Gata2 and EKLF1 were detected using qRT-PCR, &#x003b2;-actin was used as a loading control, and the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown. Significant changes were detected from the group of 48&#x000a0;h induction (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs uninduced control). <bold>b</bold> EML cells were treated with or without (mock) ATRA for indicated time points, the graph showed the rate of growth plotted on a liner scale, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs Mock control</p></caption><graphic xlink:href="12864_2015_1881_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec7"><title>Over expression of p53 down regulates Malat1 expression level via transcriptional inhibition</title><p>In order to test if the p53 level in cells affects Malat1 expression, we carried out a transiently transfection experiment that enforced expression of p53 gene in EML cells for 48&#x000a0;h, and then prepared total RNA for qRT-PCR detection. Our data shows p53 expression significantly decreases Malat1 expression level. In this test, when p53 increased to 2.7 times of control, Malat1 decreased around 4 times (<italic>P</italic>&#x02009;=&#x02009;0.003&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>). Based on this observation, we further test if p53 can affect the transcription activity by performing CHIP experiment using above transfected EML cells, the result shows there was less target sequence can be enriched on Malat1 promoter region by anti-pol II antibody (2 fold difference, <italic>P</italic>&#x02009;=&#x02009;0.00016&#x02009;&#x0003c;&#x02009;0.05) in p53 over expressed EML cells (Figs.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref> and <xref rid="Fig5" ref-type="fig">5c</xref>). We then predicted the p53 binding sites on promoter region of Malat1 using &#x0201c;PROMO&#x0201d; program (Promoter 2.0 Prediction Server), two typical p53 binding domains have been predicated that the region of (&#x02212;698 to&#x02212;669&#x000a0;bp) named as p53-BS-1 locus, the region of (&#x02212;656 to&#x02212;625&#x000a0;bp) named as p53-BS-2 locus (Figs.&#x000a0;<xref rid="Fig6" ref-type="fig">6a and 6b</xref>). We picked up these two sites for CHIP assay experiments by using anti-p53 antibody. Around 4 fold of target sequence was enriched on p53-BS-1 locus (<italic>P</italic>&#x02009;=&#x02009;0.00018&#x02009;&#x0003c;&#x02009;0.05), but no significant enrichment on BS-p53-2 locus.<fig id="Fig5"><label>Fig. 5</label><caption><p>p53 bound to Malat1 promoter and inhibited its expression. <bold>a</bold> Over expression of p53 protein (around 2.7 fold&#x000a0;up regulation) in EML cells down regulated Malat1 level with around 4 times, &#x003b2;-actin was used as a loading control, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 (over expression of P53 vs Mock control). <bold>b</bold> CHIP assay to detect the cells with over expression of p53 gene. Rabbit IgG was used as the negative control of CHIP, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs Mock control (co-immunoprecipitated with rabbit IgG). <bold>c</bold> Schematic drawing shows RNA polymerase II initiation complex binds to Malat1 promoter region, and p53 protein inhibits DNA binding activity of pol II therefore interferes the initiation complex assembly on transcription start site as indicated in the figure</p></caption><graphic xlink:href="12864_2015_1881_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>p53 regulated the expression&#x000a0;of Malat1 via sequence specific binding. <bold>a</bold> CHIP assay showed p53 protein bound to BS-p53-1 but BS-p53-2 site, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs Mock control (co-immunoprecipitated with rabbit IgG). <bold>b</bold> Schematic drawing shows the sequence specific binding of repression. The BS-p53-1 site with conserved sequence of cGGCATG has strong p53 binding activity therefore inhibits Malat1 expression</p></caption><graphic xlink:href="12864_2015_1881_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><sec id="Sec9"><title>Malat1 may preserve the proliferation ability of hematopoietic stem cells</title><p>As a typical tumor marker, Malat1 expresses with high level in malignant cells. In this study we found Malat1 gene expresses with high level in undifferentiated hematopoietic stem cells and primitive progenitor cells, down regulation of Malat1 accompanies with growth inhibition of EML cells. Our experiments have proved that p53 is acted as a transcription repressor of Malat1 expression to inhibit Malat1 activation. It has been identified that interferes p53 expression inhibits hematopoietic and muscle differentiation [<xref ref-type="bibr" rid="CR33">33</xref>], reverse function of Malat1 vs. p53 implies Malat1 preserves the ability to enhance the proliferation and inhibit differentiation of hematopoietic and muscle cells. Increased p53 expression causes cell differentiation has been recently suggested by some observations [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. In addition, interferes with endogenous wt-p53 protein of non transformed murine cells 32D (myeloid progenitors) and C2C12 (myoblasts) using dominant negative p53 protein also shows a dramatic inhibition effect of terminal differentiation into granulocytes or myotubes respectively [<xref ref-type="bibr" rid="CR37">37</xref>]. In this study, we identified that the proliferation ability of hematopoietic cells is significantly inhibited by interfering Malat1 expression in EML cells (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7b</xref>). Taken together, interfering endogenous Malat1 expression directly inhibits cell differentiation, and that Malat1 acts in opposite direction with p53 in EML cells preserves the proliferation ability of hematopoietic stem cells/progenitors.<fig id="Fig7"><label>Fig. 7</label><caption><p>Interfered Malat1 expression didn&#x02019;t significantly change the hematopoietic differentiation but inhibited the proliferation&#x000a0;of EML cells. <bold>a</bold> Inhibited Malat1 expression of EML cells by RNA interference, the decrease of Malat1 didn&#x02019;t significantly change the expression of hematopoietic factor GATA2 and EKLF1, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs Mock control (control RNAi oligo). <bold>b</bold> EML cells were interfered with control RNAi oligo or Malat1 RNAi oligo, cell number was counted at 24 and 48&#x000a0;h, the graph showed the growth rate of EML cells plotted on a liner scale, the means&#x02009;&#x000b1;&#x02009;SD of three independent experiments are shown, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs Mock control (control RNAi oligo). <bold>c</bold> Schematic drawing shows a work model that ATRA induces hematopoietic differentiation and Malat1 down regulation. In this model, ATRA induces up regulation of GATA2, EKLF1 and tumor repressor p53, and therefore causes hematopoietic differentiation, on the other hand, p53 acts as a transcription factor inhibits Malat1 expression in EML cells, Malat1 played a role in maintaining proliferation potential of hematopoietic cells</p></caption><graphic xlink:href="12864_2015_1881_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec10"><title>p53 protein down regulates Malat1 expression via sequence specific binding</title><p>ATRA induces hematopoietic differentiation of EML cells is determined by up regulation of GATA2 and EKLF1 level. Our study has proved this differentiation accompanies with up regulation of p53 and down regulation of Malat1. Surprisingly, p53 protein binds to Malat1 core promoter region, and CHIP data shows p53 can be enriched in the region of (&#x02212;652 to &#x02212;765&#x000a0;bp), the core binding loci is in the range of&#x02212;669 to&#x02212;698&#x000a0;bp, in which has the sequence of cggCATGgccgccaaggtcgccGTGCCct. Another predicted loci is in the range of (&#x02212;558 to&#x000a0;&#x02212;670&#x000a0;bp), the core binding loci is in the range of (&#x02212;625 to&#x000a0;&#x02212;656&#x000a0;bp), in which has the sequence of CATGgccttgctgGGCTGAgaccgcagcct, however, CHIP result shows the second site doesn&#x02019;t effectively bind with p53 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). Therefore we speculate even both sites (p53-BS1 and p53-BS2) have conserved CATG sequence domain, but only p53-BS1 binds to p53 protein and inhibited Malat1 gene activation, hence the background sequence of p53-BS1 with conserved domain CATG may favor a configuration of p53 binding. Our finding is consistent with some expression study of p53, for example, viral protein dysregulated p53 expression leads to up regulation&#x000a0;of Malat1, and mutation or inactivation of p53 is also shown up regulation of Malat1 expression [<xref ref-type="bibr" rid="CR38">38</xref>]. Therefore we conclude that p53 is a negative regulator of Malat1, over expression of p53 may play a therapy effect to target inhibition of oncogenic Malat1 level in cells.</p></sec><sec id="Sec11"><title>Proliferation suppression by down regulation of Malat1 in hematopoietic cells</title><p>Apparently, our study has proved Malat1 down regulates in late stage hematopoietic progenitors and more differentiated primitive cells, and Malat1 gene expression is inhibited by tumor repressor p53 protein. If down regulation of Malat1 leads to hematopoietic differentiation via proliferation inhibition? In order to answer this question, we interfered Malat1 expression of EML cells, in this study Malat1 was down regulated with 7&#x02013;8 fold (<italic>P</italic>&#x02009;=&#x02009;0.001&#x02009;&#x0003c;&#x02009;0.05), but hematopoietic differentiation marker GATA2 and EKLF1 didn&#x02019;t significantly change the expression level (<italic>P</italic>&#x02009;=&#x02009;0.15&#x02009;&#x0003e;&#x02009;0.05 for GATA2 comparison and <italic>P</italic>&#x02009;=&#x02009;0.13&#x02009;&#x0003e;&#x02009;0.05 for EKLF1 comparison. Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7a</xref>). Hence over expression of Malat1 can&#x02019;t directly drive the hematopoietic differentiation, however, the down regulation of this gene can significantly reduced hematopoietic cell (EML) proliferation rate (<italic>P</italic>&#x02009;=&#x02009;0.0312&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7b</xref>), whereas, we speculate one of the ability for Malat1 is maintained the proliferation potential of hematopoietic stem cells/progenitors. This result is also consistent with the studies from knockdown of Malat1 in myoblast [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Based on these studies we proposed a model regarding Malat1 function (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7c</xref>), during hematopoietic differentiation of EML cells by retinoic acid exposure, RA induces up regulation of GATA2 and EKLF1, then initiates hematopoietic differentiation; in the meantime, up regulation of p53 also results in regulation of downstream gene expression including negative regulation of Malat1, thus causes proliferation suppression. The mechanisms for Malat1 RNA regulating cell proliferation are still unclear.</p></sec></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusions</title><p>Malat1 is one of the most significant molecules of long non-coding RNA (lncRNA), which is commonly up regulated in malignant cells, hence it is usually considered as a biomarker of some type of cancers. Our research has clarified the aspects of normal biological function and transcriptional regulation during hematopoiesis. A, Malat1 down regulates during hematopoietic differentiation induced via ATRA; B, p53 is a negative regulator of Malat1 expression through binding to its promoter region; C, Malat1plays a critical role in maintaining the proliferation potential of early-stage hematopoietic cells. In summary, our research is the first report that Malat1 plays a role in maintaining the proliferation potential of hematopoietic cells. And Malat1 is transcriptionally regulated by tumor suppressor p53 during ATRA induced hematopoiesis.</p></sec><sec id="Sec13" sec-type="materials|methods"><title>Methods</title><sec id="Sec14"><title>Cell culture</title><p>EML cells (Multipotent hematopoietic cell line, progenitor cells of myeloid, erthroid and megakaryocytic and B-lymphoid lineages) were cultured with Iscove&#x02019;s Modified Dulbecco&#x02019;s Media (IMDM), supplemented with 20&#x000a0;% heat inactivated horse serum, and conditioned medium from cultured BHK/MKL cells was used as the source of stem cell factors. EML cells were induced to differentiate by 10&#x000a0;&#x003bc;M all-trans retinoic acid (ATRA) for indicated time points as showed in figures (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref> upper and bottom). Epro cells were cultured with IMDM containing 20&#x000a0;% horse serum and 10&#x000a0;% HM-5 conditioned medium as the source of mouse GM-CSF. All growth mediums contained 5 U/ml penicillins, 5&#x000a0;&#x003bc;g/ml streptomycin sulfate, and 2&#x000a0;mM&#x000a0;l-glutamine (Invitrogen).</p></sec><sec id="Sec15"><title>RNA interferences (RNAi)</title><p>Malat1 expression was silenced by RNA interference, briefly, used the BLOCK-iT&#x02122; online program to pick up DNA sequences that locate in ORF region of mouse Malat1 gene as following: MA-siRNA-285: GCAGTTTAGGAGATTGTAA (control oligo: MA-ctr-siRNA-285: GCAGATTAGAGGTTTGTAA); MA-siRNA-2247: GCGGAATTGCTGGTAGTTT (Control oligo: MA-ctr-siRNA-2247: GCGGTTAGGTCGATAGTTT). Synthesized double strand RNAs for these oligos and transiently transfected into EML cells as following: 30&#x000a0;&#x003bc;l of Lipofectamin 2000 was mixed with 1.5&#x000a0;ml of Opiti-MEM medium, then incubated at RT for 5&#x000a0;min, mixed 75&#x000a0;&#x003bc;l of double strand RNA (20&#x000a0;&#x003bc;M) with 1.5&#x000a0;ml of Opiti-MEM medium, incubated at RT for another 5&#x000a0;min. Mixed RNAs and Lipofectamine solution and incubated at RT for total 20&#x000a0;min. Harvested EML cells with spin and then resuspended <bold>~</bold>2X107cells with 1.5&#x000a0;ml of Opiti-MEM medium, added RNA-Lipofectamin mixture to these cells and mixed gently, then incubated for 48&#x000a0;h in a CO<sub>2</sub> incubator.</p></sec><sec id="Sec16"><title>Chromatin precipitation (CHIP) and promoter binding assay</title><p>ChIP assays were performed using chromatin immunoprecipitation assay kit (Upstate) following manufacturer's instruction. EML cells (2X106) were plated per 100-mm dish before 24&#x000a0;h transfection, and then transfected with 24&#x000a0;&#x003bc;g indicated plasmids. After 48&#x000a0;h transfection, harvested cells and cross linked with fixing buffer (1&#x000a0;% formaldehyde, 10&#x000a0;mM NaCl, 50 mMHePes, pH7.5, 1&#x000a0;mM EDTA, 0.5&#x000a0;mM EGTA), prepared nuclear extracts and then fragmentized chromatin DNA into an average of 200&#x000a0;bp segments by sonication. Chip assays were performed with anti-p53 and anti-pol II antibodies, reversed precipitated DNA-protein complex and purified DNA fragments, then performed quantitative PCR using QuantiTect SYBR Green PCR master mix (Qiagen). Primers were used as following: for p53 binding site assay: Site 1: FMA53-1, gatagacctggggaccttgc, RMA53-1, atggtcgctgcaggtgag, the amplified fragment was 113&#x000a0;bp; Site 2: FMA53-2, ctcacctgcagcgaccat, RMA53-2: ctctcggggccacttttc, and the amplified fragment was 112&#x000a0;bp. For pol II binding site assay, Fpol: tcgtccctacaggagcattc, Rpol: cagcttcagcttccacttcc, and the amplified fragment was 160&#x000a0;bp.</p></sec><sec id="Sec17"><title>RNA isolation, Northern blot and qPCR /qRT-PCR</title><p>Total RNA was isolated from EML, EPRO and isolated bone marrow cells using trizol reagent (Life Technologies, Gaithersberg, MD). Northern blot was performed with 10&#x000a0;&#x003bc;g total RNA per lane. Probe for detecting Malat1 was 225&#x000a0;bp of 5&#x02019; sequence (spanning 72-296&#x000a0;bp of the sequence of Genebank Accession number HG982261.1). Probe for detecting &#x003b2;-actin was 202&#x000a0;bp of 5&#x02019; sequence (spanning 490&#x02013;691&#x000a0;bp of the sequence of Genebank Accession number X03672). A mouse multiple tissue RNA blot was purchased from Clontech. The probes were labeled using PCR amplification that <sup>32</sup>P-labeled dCTP was incorporated into produced PCR fragments. RNA was electrophoresed on a 1&#x000a0;% agrose/formaldehyde gel and was blotted onto membranes (Amersham Pharmacia Biotech) followed by UV crosslinking. The hybridization was performed at 65&#x000a0;&#x000b0;C for 16&#x000a0;h. Signals on the washed membrane were visualized by autoradiography and were quantitated by densitometry analysis. The qPCR or qRT-PCR was performed as previously described.</p></sec><sec id="Sec18"><title>Purification of LRH and LRB cells from mouse bone marrow</title><p>Prepared bone marrow cells from 8&#x02013;12-week-old BALB/c mice, then depleted lineage positive cells by using a mixture of phycoerythrin (PE)<bold>&#x02013;</bold>conjugated monoclonal antibodies directed against surface antigens (derived from blood cells including CD11b, CD5, CD8a, CD4, Gr-1, CD45R, Ter119) were purchased from BD Biosciences (San Jose, CA) and PE magnetic beads were purchased from Miltenyi Biotech (Surrey, U.K.). Purified Lin (-) cells were then further purified using a cocktail solution of supravital dyes. Principally, Lin- cells were suspended in FACS stain buffer (1XHBSS buffer) containing Rhodamine-123 and Hoechst-33342 for 15&#x000a0;min; labeled cells were then sorted on FACS-STAR (Becton Dickinson), the Lin-Rho<sup>low</sup>/Hoechst<sup>Bright</sup>(LRB) represented late stage progenitor cells and the Lin-Rho<sup>low</sup>/Hoechst<sup>Low</sup>(LRH) represented more primitive progenitor cells, were highly enriched from Lin- population and used for Malat1 expression analysis.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p>The mean value and standard deviation of three independent experiments were used. P values were calculated with a paired student&#x02019;s <italic>T</italic> test (two tailed hypothesis). A <italic>P</italic> value of&#x02009;&#x0003c;&#x02009;0.05 between experimental sample (group) and control sample (group) was considered to be statistically significance.</p></sec><sec id="Sec20"><title>Availability of supporting data</title><p>The Malat1 sequences and the phylogenetic tree of 20 species of mammals in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref> are available in Dryad repository, DOI: doi:10.5061/dryad.017t8.</p><p>The expression datasets of 7 tissues from 12 different primate species in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> are from <ext-link ext-link-type="uri" xlink:href="http://www.nhprtr.org/data/2014_NHP_tissuespecific">http://www.nhprtr.org/data/2014_NHP_tissuespecific</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/ieb/research/acembly/av.cgi?db=human">http://www.ncbi.nlm.nih.gov/ieb/research/acembly/av.cgi?db=human</ext-link>.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ATRA</term><def><p>All-trans Retinoic Acid</p></def></def-item><def-item><term>ChIP</term><def><p>Immunoprecipitation</p></def></def-item><def-item><term>EML</term><def><p>Erythroid myeloid lymphoid</p></def></def-item><def-item><term>hESC</term><def><p>Human embryonic stem cell</p></def></def-item><def-item><term>iPSC</term><def><p>Induced pluripotent stem cell</p></def></def-item><def-item><term>lncRNA</term><def><p>Long non-coding RNA</p></def></def-item><def-item><term>SR proteins</term><def><p>Serine/arginine (SR)-rich Proteins</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>XYM Performed experimental design, Northern blot analysis and drafted the manuscript. JHW carried out the data analysis. JLW performed the qRT-PCR analysis. CXM assisted with experimental work of cell growth and proliferation. XCW participated in the data analysis and CHIP-PCR experiment. FSL involved in conceiving the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Work in authors&#x02019; laboratory is supported in part by National Institute of Health</p><p>Grant CA-85995/CA/NCI NIH. We thank Dr. Krause for her generous and excellent help, Professor Jeffrey Sklar for critical support during this research. This work was also financially supported by the Natural Science Foundation of Hebei Province, China (No.C2015201013) and the National Natural Science Foundation of China (No. 31101669).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Diederichs</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Boing</surname><given-names>S</given-names></name><name><surname>Metzger</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>PM</given-names></name><name><surname>Tidow</surname><given-names>N</given-names></name><name><surname>Brandt</surname><given-names>B</given-names></name><name><surname>Buerger</surname><given-names>H</given-names></name><name><surname>Bulk</surname><given-names>E</given-names></name><etal/></person-group><article-title>MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><issue>39</issue><fpage>8031</fpage><lpage>8041</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206928</pub-id><?supplied-pmid 12970751?><pub-id pub-id-type="pmid">12970751</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Kano</surname><given-names>J</given-names></name><name><surname>Tsunoda</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Okubo</surname><given-names>C</given-names></name><name><surname>Ishiyama</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name></person-group><article-title>Phenotypic characterization of endometrial stromal sarcoma of the uterus</article-title><source>Cancer Sci</source><year>2006</year><volume>97</volume><issue>2</issue><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00147.x</pub-id><?supplied-pmid 16441420?><pub-id pub-id-type="pmid">16441420</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guffanti</surname><given-names>A</given-names></name><name><surname>Iacono</surname><given-names>M</given-names></name><name><surname>Pelucchi</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Solda</surname><given-names>G</given-names></name><name><surname>Croft</surname><given-names>LJ</given-names></name><name><surname>Taft</surname><given-names>RJ</given-names></name><name><surname>Rizzi</surname><given-names>E</given-names></name><name><surname>Askarian-Amiri</surname><given-names>M</given-names></name><name><surname>Bonnal</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>A transcriptional sketch of a primary human breast cancer by 454 deep sequencing</article-title><source>BMC Genomics</source><year>2009</year><volume>10</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-10-163</pub-id><?supplied-pmid 19379481?><pub-id pub-id-type="pmid">19379481</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion</article-title><source>Acta Biochim Biophys Sin</source><year>2010</year><volume>42</volume><issue>3</issue><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmq008</pub-id><?supplied-pmid 20213048?><pub-id pub-id-type="pmid">20213048</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>MALAT-1: a long non-coding RNA and its important 3&#x02019; end functional motif in colorectal cancer metastasis</article-title><source>Int J Oncol</source><year>2011</year><volume>39</volume><issue>1</issue><fpage>169</fpage><lpage>175</lpage><?supplied-pmid 21503572?><pub-id pub-id-type="pmid">21503572</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>JH</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Keryanov</surname><given-names>S</given-names></name><name><surname>Tseng</surname><given-names>GC</given-names></name><name><surname>Rao</surname><given-names>UN</given-names></name><name><surname>Monga</surname><given-names>SP</given-names></name><name><surname>Strom</surname><given-names>S</given-names></name><name><surname>Demetris</surname><given-names>AJ</given-names></name><name><surname>Nalesnik</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><issue>4</issue><fpage>1012</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1002/hep.21328</pub-id><?supplied-pmid 17006932?><pub-id pub-id-type="pmid">17006932</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine</article-title><source>Modern Pathology: Off J United States Canadian Acad Pathology Inc</source><year>2013</year><volume>26</volume><issue>2</issue><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.160</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshimizu</surname><given-names>TA</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name></person-group><article-title>Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line</article-title><source>Life Sci</source><year>2010</year><volume>86</volume><issue>11-12</issue><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2010.02.001</pub-id><?supplied-pmid 20149803?><pub-id pub-id-type="pmid">20149803</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipovich</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name></person-group><article-title>MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long nonprotein-coding RNA</article-title><source>Biochimicaetbiophysicaacta</source><year>2010</year><volume>1799</volume><issue>9</issue><fpage>597</fpage><lpage>615</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Dang</surname><given-names>YW</given-names></name><name><surname>Li</surname><given-names>CJ</given-names></name><name><surname>Luo</surname><given-names>DZ</given-names></name></person-group><article-title>Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues</article-title><source>APJCP</source><year>2014</year><volume>15</volume><issue>7</issue><fpage>2971</fpage><lpage>2977</lpage><?supplied-pmid 24815433?><pub-id pub-id-type="pmid">24815433</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer</article-title><source>J Urol</source><year>2013</year><volume>190</volume><issue>6</issue><fpage>2278</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.07.001</pub-id><?supplied-pmid 23845456?><pub-id pub-id-type="pmid">23845456</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>The complexity of bladder cancer: long noncoding RNAs are on the stage</article-title><source>Mol Cancer</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-12-101</pub-id><?supplied-pmid 24006935?><pub-id pub-id-type="pmid">24006935</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name></person-group><article-title>MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF</article-title><source>Biomed Pharmacother</source><year>2014</year><volume>68</volume><issue>(5</issue><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2014.04.007</pub-id><?supplied-pmid 24857172?><pub-id pub-id-type="pmid">24857172</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutschner</surname><given-names>T</given-names></name><name><surname>H&#x000e4;mmerle</surname><given-names>M</given-names></name><name><surname>Eissmann</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Hung</surname><given-names>G</given-names></name><name><surname>Revenko</surname><given-names>A</given-names></name><name><surname>Arun</surname><given-names>G</given-names></name><name><surname>Stentrup</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>M</given-names></name><etal/></person-group><article-title>The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><issue>3</issue><fpage>1180</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2850</pub-id><?supplied-pmid 23243023?><pub-id pub-id-type="pmid">23243023</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Johnsen</surname><given-names>VL</given-names></name><name><surname>Shearer</surname><given-names>J</given-names></name><name><surname>Hittel</surname><given-names>DS</given-names></name></person-group><article-title>Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis</article-title><source>Am J Physiol Cell Physiol</source><year>2013</year><volume>304</volume><issue>10</issue><fpage>C995</fpage><lpage>C1001</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00392.2012</pub-id><?supplied-pmid 23485710?><pub-id pub-id-type="pmid">23485710</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Pedrosa</surname><given-names>E</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Hrabovsky</surname><given-names>A</given-names></name><name><surname>Maqbool</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Lachman</surname><given-names>HM</given-names></name></person-group><article-title>RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>9</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0023356</pub-id><?supplied-pmid 21915259?><pub-id pub-id-type="pmid">21915259</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kryger</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Wilce</surname><given-names>PA</given-names></name><name><surname>Jaquet</surname><given-names>V</given-names></name></person-group><article-title>MALAT-1, a non protein-coding RNA is upregulated in the cerebellum, hippocampus and brain stem of human alcoholics</article-title><source>Alcohol</source><year>2012</year><volume>46</volume><issue>7</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2012.04.002</pub-id><?supplied-pmid 22560368?><pub-id pub-id-type="pmid">22560368</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le-Niculescu</surname><given-names>H</given-names></name><name><surname>Balaraman</surname><given-names>Y</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Sidhu</surname><given-names>K</given-names></name><name><surname>Jerome</surname><given-names>RE</given-names></name><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Kuczenski</surname><given-names>R</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Towards understanding the schizophrenia code: an expanded convergent functional genomics approach</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2007</year><volume>144B</volume><issue>2</issue><fpage>129</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.30481</pub-id><?supplied-pmid 17266109?><pub-id pub-id-type="pmid">17266109</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>LS</given-names></name><name><surname>Angus</surname><given-names>IL</given-names></name></person-group><article-title>Nuclear Speckes</article-title><source>Cold Spring Harb Perspect Biol</source><year>2011</year><volume>3</volume><issue>2</issue><fpage>a000646</fpage><pub-id pub-id-type="pmid">20926517</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Ellis</surname><given-names>JD</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>DY</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Watt</surname><given-names>AT</given-names></name><name><surname>Freier</surname><given-names>SM</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Bubulya</surname><given-names>PA</given-names></name><etal/></person-group><article-title>The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation</article-title><source>Mol Cell</source><year>2010</year><volume>39</volume><issue>6</issue><fpage>925</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.08.011</pub-id><?supplied-pmid 20797886?><pub-id pub-id-type="pmid">20797886</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Chakraborty</surname><given-names>A</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name><name><surname>Freier</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name><name><surname>Prasanth</surname><given-names>SG</given-names></name><name><surname>Lal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB</article-title><source>PLoS Genet</source><year>2013</year><volume>9</volume><issue>3</issue><pub-id pub-id-type="doi">10.1371/journal.pgen.1003368</pub-id><?supplied-pmid 23555285?><pub-id pub-id-type="pmid">23555285</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajaram</surname><given-names>V</given-names></name><name><surname>Knezevich</surname><given-names>S</given-names></name><name><surname>Bove</surname><given-names>KE</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Pfeifer</surname><given-names>JD</given-names></name></person-group><article-title>DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t (11; 19)(q11; q13.4) translocation</article-title><source>Genes Chromosomes Cancer</source><year>2007</year><volume>46</volume><issue>5</issue><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1002/gcc.20437</pub-id><?supplied-pmid 17311249?><pub-id pub-id-type="pmid">17311249</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>IJ</given-names></name><name><surname>Hsi</surname><given-names>BL</given-names></name><name><surname>Arroyo</surname><given-names>JD</given-names></name><name><surname>Vargas</surname><given-names>SO</given-names></name><name><surname>Yeh</surname><given-names>YA</given-names></name><name><surname>Motyckova</surname><given-names>G</given-names></name><name><surname>Valencia</surname><given-names>P</given-names></name><name><surname>Perez-Atayde</surname><given-names>AR</given-names></name><name><surname>Argani</surname><given-names>P</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Cloning of an Alpha-TFEB fusion in renal tumors harboring the t (6; 11)(p21; q13) chromosome translocation</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><issue>10</issue><fpage>6051</fpage><lpage>6056</lpage><pub-id pub-id-type="doi">10.1073/pnas.0931430100</pub-id><?supplied-pmid 12719541?><pub-id pub-id-type="pmid">12719541</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>LA</given-names></name><name><surname>Christensen</surname><given-names>CJ</given-names></name><name><surname>Dunn</surname><given-names>DM</given-names></name><name><surname>Spangrude</surname><given-names>GJ</given-names></name><name><surname>Georgelas</surname><given-names>A</given-names></name><name><surname>Kelley</surname><given-names>L</given-names></name><name><surname>Esplin</surname><given-names>MS</given-names></name><name><surname>Weiss</surname><given-names>RB</given-names></name><name><surname>Gleich</surname><given-names>GJ</given-names></name></person-group><article-title>EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression</article-title><source>Blood</source><year>2007</year><volume>109</volume><issue>12</issue><fpage>5191</fpage><lpage>5198</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-06-027987</pub-id><?supplied-pmid 17351112?><pub-id pub-id-type="pmid">17351112</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>Z</given-names></name><name><surname>Padden</surname><given-names>C</given-names></name><name><surname>Gerstein</surname><given-names>MB</given-names></name><name><surname>Rozowsky</surname><given-names>J</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name><name><surname>Kapranov</surname><given-names>P</given-names></name><name><surname>Weissman</surname><given-names>SM</given-names></name><name><surname>Newburger</surname><given-names>PE</given-names></name></person-group><article-title>A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster</article-title><source>Blood</source><year>2009</year><volume>113</volume><issue>11)</issue><fpage>2526</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-06-162164</pub-id><?supplied-pmid 19144990?><pub-id pub-id-type="pmid">19144990</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Weissman</surname><given-names>SM</given-names></name><name><surname>Newburger</surname><given-names>PE</given-names></name></person-group><article-title>Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells</article-title><source>RNA Biol</source><year>2014</year><volume>11</volume><issue>6</issue><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.4161/rna.28828</pub-id><?supplied-pmid 24824789?><pub-id pub-id-type="pmid">24824789</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>XY</given-names></name><name><surname>Ma</surname><given-names>XC</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name></person-group><article-title>Long Non-Coding RNA Malat1 Regulates Gene Expression and Protein Function via Multiple-Layer and Flexible Manners</article-title><source>Austin J Pathology Lab Med</source><year>2014</year><volume>1</volume><issue>3</issue><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Inheritable and Precise Large Genomic Deletions of Non-Coding RNA Genes in Zebrafish Using TALENs</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>10</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0076387</pub-id><?supplied-pmid 24130773?><pub-id pub-id-type="pmid">24130773</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>HP</given-names></name><name><surname>Malu</surname><given-names>K</given-names></name><name><surname>Berliner</surname><given-names>N</given-names></name><name><surname>Gaines</surname><given-names>P</given-names></name></person-group><article-title>Differentiation and characterization of myeloid cells</article-title><source>Curr Protoc Immunol</source><year>2014</year><volume>104</volume><fpage>Unit 22F 25</fpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KD</given-names></name><name><surname>Hsu</surname><given-names>AP</given-names></name><name><surname>Ryu</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Boyer</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Calvo</surname><given-names>KR</given-names></name><name><surname>Keles</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><issue>10</issue><fpage>3692</fpage><lpage>3704</lpage><pub-id pub-id-type="doi">10.1172/JCI61623</pub-id><?supplied-pmid 22996659?><pub-id pub-id-type="pmid">22996659</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drissen</surname><given-names>R</given-names></name><name><surname>von Lindern</surname><given-names>M</given-names></name><name><surname>Kolbus</surname><given-names>A</given-names></name><name><surname>Driegen</surname><given-names>S</given-names></name><name><surname>Steinlein</surname><given-names>P</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name><name><surname>Philipsen</surname><given-names>S</given-names></name></person-group><article-title>The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><issue>12</issue><fpage>5205</fpage><lpage>5214</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.12.5205-5214.2005</pub-id><?supplied-pmid 15923635?><pub-id pub-id-type="pmid">15923635</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frontelo</surname><given-names>P</given-names></name><name><surname>Manwani</surname><given-names>D</given-names></name><name><surname>Galdass</surname><given-names>M</given-names></name><name><surname>Karsunky</surname><given-names>H</given-names></name><name><surname>Lohmann</surname><given-names>F</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>Bieker</surname><given-names>JJ</given-names></name></person-group><article-title>Novel role for EKLF in megakaryocyte lineage commitment</article-title><source>Blood</source><year>2007</year><volume>110</volume><issue>12</issue><fpage>3871</fpage><lpage>3880</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-03-082065</pub-id><?supplied-pmid 17715392?><pub-id pub-id-type="pmid">17715392</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soddu</surname><given-names>S</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Scardigli</surname><given-names>R</given-names></name><name><surname>Coen</surname><given-names>S</given-names></name><name><surname>Marchetti</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>MG</given-names></name><name><surname>Bossi</surname><given-names>G</given-names></name><name><surname>Cimino</surname><given-names>L</given-names></name><name><surname>Crescenzi</surname><given-names>M</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name></person-group><article-title>Interference with p53 protein inhibits hematopoietic and muscle differentiation</article-title><source>J Cell Biol</source><year>1996</year><volume>134</volume><issue>1</issue><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1083/jcb.134.1.193</pub-id><?supplied-pmid 8698814?><pub-id pub-id-type="pmid">8698814</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocchia</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wesley</surname><given-names>U</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Korontsvit</surname><given-names>T</given-names></name><name><surname>Loganzo</surname><given-names>F</given-names></name><name><surname>Albino</surname><given-names>AP</given-names></name><name><surname>Scheinberg</surname><given-names>DA</given-names></name></person-group><article-title>Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells</article-title><source>Leuk Res</source><year>1997</year><volume>21</volume><issue>5</issue><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/S0145-2126(96)00085-9</pub-id><?supplied-pmid 9225073?><pub-id pub-id-type="pmid">9225073</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halevy</surname><given-names>O</given-names></name></person-group><article-title>p53 gene is up-regulated during skeletal muscle cell differentiation</article-title><source>Biochem Biophys Res Commun</source><year>1993</year><volume>192</volume><issue>2</issue><fpage>714</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1993.1473</pub-id><?supplied-pmid 8484778?><pub-id pub-id-type="pmid">8484778</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Perez-Stable</surname><given-names>C</given-names></name><name><surname>D&#x02019;Ippolito</surname><given-names>G</given-names></name><name><surname>Schiller</surname><given-names>PC</given-names></name><name><surname>Roos</surname><given-names>BA</given-names></name><name><surname>Howard</surname><given-names>GA</given-names></name></person-group><article-title>Human bone marrow-derived stem cell proliferation is inhibited by hepatocyte growth factor via increasing the cell cycle inhibitors p53, p21 and p27</article-title><source>Bone</source><year>2011</year><volume>49</volume><issue>6</issue><fpage>1194</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2011.08.023</pub-id><?supplied-pmid 21907315?><pub-id pub-id-type="pmid">21907315</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaro</surname><given-names>G</given-names></name><name><surname>Bossi</surname><given-names>G</given-names></name><name><surname>Coen</surname><given-names>S</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><name><surname>Soddu</surname><given-names>S</given-names></name></person-group><article-title>The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><issue>42</issue><fpage>5831</fpage><lpage>5835</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202962</pub-id><?supplied-pmid 10523864?><pub-id pub-id-type="pmid">10523864</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Jeffers LK, Duan K, Ellies LG, Seaman WT, Burger-Calderon RA, Diatchenko LB, et al. Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p53 in small DNA tumor virus models. J Cancer Ther. 2013;4(3).</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Ghozlan</surname><given-names>M</given-names></name><name><surname>Hughey</surname><given-names>CC</given-names></name><name><surname>Johnsen</surname><given-names>VL</given-names></name><name><surname>Shearer</surname><given-names>J</given-names></name><name><surname>Hittel</surname><given-names>DS</given-names></name></person-group><article-title>Myostatin inhibits proliferation and insulin-stimulated glucose uptake in mouse liver cells</article-title><source>Biochemistry and Cell Biology-Biochimie et Biologie Cellulaire</source><year>2014</year><volume>92</volume><issue>3</issue><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1139/bcb-2014-0004</pub-id><?supplied-pmid 24882465?><pub-id pub-id-type="pmid">24882465</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalik</surname><given-names>KM</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Manavski</surname><given-names>Y</given-names></name><name><surname>Doddaballapur</surname><given-names>A</given-names></name><name><surname>Z&#x000f6;rnig</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Ponomareva</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><issue>9</issue><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303265</pub-id><?supplied-pmid 24602777?><pub-id pub-id-type="pmid">24602777</pub-id></element-citation></ref></ref-list></back></article>